The Alpha-1 Foundation is committed to finding a cure for Alpha-1 Antitrypsin Deficiency and to improving the lives of individuals affected by Alpha-1 worldwide.

The specific aims of the Grants Award Program are to promote research that would eventually result in the improved health of individuals with AAT Deficiency. The Program supports basic science and clinical research, improved understanding of the pathogenesis of the clinical manifestations of AAT Deficiency, the development and testing of treatments for the disease, bioethics and social research, and the promotion of education of members of the medical community regarding AAT Deficiency.

The Grants Award Program is the Alpha-1 Foundation’s mechanism to fund a broad range of research that leads to improvements in the lives of people living with AAT Deficiency. The specific goals of the Program are 1) to promote basic science and clinical research related to the alpha1 antitrypsin protein and AAT Deficiency; 2) to attract and train clinical researchers for the study of AAT Deficiency; 3) to support and encourage established scientists to work on clinical problems and ethical, legal, and social issues within the field of AAT research (with a preference given to new investigators); and ultimately, 4) to develop effective therapies for the clinical manifestations of AAT Deficiency.

The Alpha-1 Foundation will support a broad spectrum of research projects involving basic science, translational and clinical research, and ethical, legal, and social issues. The Foundation’s research agenda can be found on the Foundation’s website at www.alpha1.org.

Deadline for Letter of Intent: Sep. 30, 2022